A strong end to the year for its cough and cold portfolio after a difficult first half helped Recordati Industria Chimica & Farmaceutica SPA to record a small rise in OTC sales in 2024.
The Milan, Italy-based firm posted OTC turnover up by 1.1% to €335m ($362m) as its winter illness brands benefitted from increased demand in the fourth quarter. Lower sales of cough...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?